ENSEMBLE PLUS: final results of shorter ocrelizumab infusion from a randomized controlled trial

ConclusionENSEMBLE PLUS demonstrates the safety and tolerability of shorter ocrelizumab infusions. Most patients remained on/switched to shorter infusion after unblinding; IRRs did not strongly influence patient decisions.Clinical Trials Registration: Substudy of ENSEMBLE (NCT03085810). Registration: March 21, 2017.
Source: Journal of Neurology - Category: Neurology Source Type: research